TCRX Stock Summary and Trading Ideas (Tscan Therapeutics | NASDAQ:TCRX)

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Tscan Therapeutics trades on the NASDAQ stock market under the symbol TCRX.

As of June 17, 2026, TCRX stock price climbed to $0.90 with 515,216 million shares trading.

TCRX has a beta of 3.15, meaning it tends to be more sensitive to market movements. TCRX has a correlation of 0.18 to the broad based SPY ETF.

TCRX has a market cap of $58.81 million. This is considered a Micro Cap stock.

Last quarter Tscan Therapeutics reported $982,000 in Revenue and -$.22 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.04.

In the last 3 years, TCRX traded as high as $9.69 and as low as $.85.

The top ETF exchange traded funds that TCRX belongs to (by Net Assets): VTI, VXF, IWC.

TCRX has underperformed the market in the last year with a price return of -41.6% while the SPY ETF gained +25.2%. TCRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.4% and -7.4%, respectively, while the SPY returned +10.7% and -1.8%, respectively.

TCRX support price is $.81 and resistance is $.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TCRX shares will trade within this expected range on the day.